NEW BRUNSWICK, N.J., Jan. 15, 2016 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast focused on data from the Janssen Oncology hematologic malignancy portfolio for investors and other interested parties on Friday, January 15.
The pre-recorded webcast features Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head of Oncology for Janssen R&D, recapping key data presentations on DARZALEX™ (daratumumab) and IMBRUVICA® (ibrutinib) that were featured at the 2015 American Society of Hematology (ASH) Annual meeting. Dr. Lebowitz will also describe the development plans for these and other compounds in the Janssen Oncology hematologic malignancy portfolio.
The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations." The webcast duration is approximately 18 minutes and will be available through the end of February.
SOURCE Johnson & Johnson